An Interim Report of a Phase 3, Long-Term, Open-Label Study to Evaluate Efficacy and Safety of Difamilast Ointment in Japanese Infants with Atopic Dermatitis

• Glavni autori: Hidehisa Saeki (Autor), Yukihiro Ohya (Autor), Naoko Baba (Autor), Tomomi Imamura (Autor), Daisuke Yokota (Autor), Hidetsugu Tsubouchi (Autor)
• Format: Knjiga
• Izdano: Adis, Springer Healthcare, 2024-07-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Abstract Introduction Difamilast is the first selective phosphodiesterase 4 inhibitor approved for atopic dermatitis (AD) in Japan. A phase 3, 52-week, open-label study is ongoing to establish efficacy and safety of difamilast ointments in infants with AD aged 3 to < 24 months because a clinical...